Breast Cancer Now media statements
Breast Cancer Now response to the death of Linda Nolan
Claire Rowney, CEO, Breast Cancer Now says:
We respond to The NHS Jewish BRCA Testing Programme identifying 235 people with higher risk of cancer
Claire Rowney, chief executive of Breast Cancer Now, said:
We respond to NICE’s provisional rejection of capivasertib with fulvestrant for certain types of secondary breast cancer
Claire Rowney, chief executive of Breast Cancer Now, said:
We respond to Audit Wales Cancer Services Report
Claire Rowney, chief executive, at Breast Cancer Now, said:
Responding to the NICE decision to approve olaparib (Lynparza) for certain people with locally advanced or secondary breast cancer who have inherited an altered BRCA gene.
Responding, Claire Rowney, chief executive at Breast Cancer Now, said:
We respond to new University of Oxford research highlighting the potential of the TriOx test to improve early cancer detection
Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said:
Breast Cancer Now responds to early diagnosis in England reaching highest level ever
In response to figures showing early cancer diagnosis in England reaching highest ever level, Claire Rowney, chief executive of Breast Cance...
Breast Cancer Now 's response to NICE final decision on elacestrant (Korserdu)
Responding, Claire Rowney, chief executive at Breast Cancer Now, said:
We respond to report revealing more than one in four premature deaths in UK 'will be due to cancer by 2050'
Responding to a new study from the Organisation for Economic Co-operation and Development (OECD), 'Tackling the Impact of Cancer on Health, ...
We respond to NICE guidance to not recommend Enhertu for HER2-low secondary breast cancer remaining unchanged
Claire Rowney, chief executive of Breast Cancer Now, says:
We respond to the National Cancer Medicines Advisory Group in Scotland supporting use of anastrozole, tamoxifen and raloxifene to reduce risk of breast cancer
Claire Rowney, chief executive at Breast Cancer Now said:
We respond to new research that suggests women who use a contraceptive coil may have a slightly higher risk of developing breast cancer
Dr Simon Vincent, director of research, services and influencing at Breast Cancer Now, said: